The American College of Radiology Imaging Network (ACRIN) and the Eastern Cooperative Oncology Group (ECOG) today unveiled their clinical research alliance: ECOG-ACRIN Cancer Research Group (ECOG-ACRIN).
The American College of Radiology Imaging Network (ACRIN) and the Eastern Cooperative Oncology Group (ECOG) today unveiled their clinical research alliance: ECOG-ACRIN Cancer Research Group (ECOG-ACRIN).
“We are already actively engaged in the shared mission of reshaping the future of patient care through clinical research that leads to earlier cancer detection, more successful therapeutic intervention, greater rates of prevention, and more successful patient outcomes,” officials of the alliance said at the 2011 ACRIN Annual Meeting on Friday. They said their two respective National Cancer Institute cooperative groups have merged their oncology research activities into three core areas of emphasis:
• Early detection and diagnosis of cancer;
• Biomarker-driven Phase II and Phase III therapeutic studies for multiple cancer types and stages; and
• Genetic, molecular and imaging marker research to predict and monitor treatment response.
The organizations seek “bold integration of disciplines and technologies,” with an eye toward conducting “definitive, groundbreaking, biomarker-driven clinical research that promises to achieve patient-centered breakthroughs.”
Integration efforts are afoot and the group’s leadership is developing the business, administrative, and scientific framework for ECOG-ACRIN to sustain and streamline its combined research portfolio through public and private support, ECOG-ACRIN officials said.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.